BioNotebook: Medivation, Clovis, Arena 4Q updates; Abide/Celgene discovery deal; 3 new IPO filers, 2 other set terms

Medivation, Clovis Oncology and Arena Pharmaceuticals waited until the end of earnings season to provide fourth quarter financial updates and they took a beating on 28 February, which was a tough day for US biotechnology stocks.